Continuing Education Activity

Lorazepam is a benzodiazepine medication approved by the US Food and Drug Administration (FDA) for short-term relief of anxiety symptoms associated with anxiety disorders, anxiety-related insomnia, anesthesia premedication in adults to relieve anxiety or induce sedation or amnesia, and treatment of status epilepticus. Lorazepam is favored in inpatient settings for its rapid onset of action (1-3 minutes intravenously). Off-label uses for lorazepam include rapid tranquilization of agitated patients, alcohol withdrawal delirium and syndrome, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough), vertigo, and psychogenic catatonia. Lorazepam is used in various clinical practices and is often compared with other benzodiazepines. Clinicians from several specialties and at different levels of practice utilize it in acute, short-term, and long-term settings. 

This activity reviews lorazepam, including its mechanism of action, adverse event profiles, and monitoring, and identifies potential drug-drug interactions through its pharmacokinetics. This activity allows participating clinicians to make decisions and optimize dosage regimens while minimizing the adverse reactions of the drug. In addition, the interprofessional healthcare team, comprising clinicians, pharmacists, and therapists, works together to provide appropriate treatment for patients with psychiatric conditions.

Objectives:

• Identify appropriate indications for lorazepam use based on patient presentation and clinical guidelines.
• Implement appropriate monitoring protocols to assess patient response and potential adverse reactions to lorazepam therapy.
• Select alternative treatment options or adjust lorazepam dosage based on individual patient characteristics and treatment goals.
• Collaborate with interprofessional healthcare teams, including pharmacists and therapists, to ensure comprehensive patient care and treatment planning.

Indications

Lorazepam is a benzodiazepine medication approved by the US Food and Drug Administration (FDA) for various conditions. The drug is used in various clinical practices and is often compared with other benzodiazepines. Lorazepam was developed by DJ Richards and was initially marketed in the United States in 1977. Lorazepam is favored in inpatient settings as the sedative and anxiolytic drug of choice for its rapid onset of action (1-3 minutes) when administered intravenously (IV).[1]  See Figure. Lorazepam Organic Chemical Structure.

FDA-Approved Indications

• Short-term (4 months) relief of anxiety symptoms associated with anxiety disorders
• Anxiety-related insomnia
• Anesthesia premedication in adults to relieve anxiety or to induce sedation or amnesia
• Treatment of status epilepticus [2] 

Off-Label Uses

• Rapid tranquilization of the agitated patient
• Alcohol withdrawal delirium and syndrome
• Insomnia
• Panic disorder
• Delirium
• Chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough)
• Psychogenic catatonia
• Vertigo [3][4][5][6][7]

Mechanism of Action

Lorazepam binds to benzodiazepine receptors on postsynaptic γ-aminobutyric acid (GABA)-A ligand-gated chloride channel neurons at multiple sites within the central nervous system (CNS). This medication enhances the inhibitory effects of GABA, which increases the conductance of chloride ions in the cell. Consequently, a shift in chloride ions leads to hyperpolarization and stabilization of the cellular plasma membrane.[8] The inhibitory action in the amygdala is beneficial in anxiety disorders, while the inhibitory activity in the cerebral cortex is beneficial in seizure disorders.

Pharmacokinetics

Absorption: Lorazepam is well absorbed after oral administration. Peak concentrations are attained 2 hours following oral administration. The bioavailability of lorazepam is approximately 90%. Moreover, lorazepam freely crosses the blood-brain barrier via passive diffusion.

Distribution: Lorazepam has a volume of distribution of 1.3 L/kg, and it binds to approximately 90% of plasma proteins. The drug crosses the blood-brain barrier via passive diffusion.

Metabolism: Lorazepam undergoes conjugation in the liver and experiences enterohepatic recirculation. Lorazepam glucuronide is an inactive metabolite. The medication undergoes direct glucuronidation without prior cytochrome p450 metabolism. Consequently, lorazepam can be safely administered to patients with hepatic dysfunction with minimal impact on its pharmacokinetics.

Excretion: Lorazepam has an elimination half-life of 14±5 hours and a clearance of 1.1±0.4 mL/min/kg. The drug is primarily excreted in the urine.[9][10]

Administration

Available Dosage Forms and Strengths

Lorazepam is available in various formulations, including oral tablets, oral concentrate solutions, extended-release capsules, and solutions.

Lorazepam can be administered orally in strengths of 0.5 mg, 1 mg, and 2 mg tablets, as well as an oral concentrate solution of 2 mg/mL. Extended-release capsules are also available in strengths of 1 mg, 2 mg, and 3 mg. Additionally, lorazepam can be administered intravenously (IV) or via intramuscular (IM) injection, with solutions available in concentrations of 2 mg/mL and 4 mg/mL. The onset of action is typically 1 to 3 minutes when administered IV and 15 to 30 minutes when administered IM.

Adult Dosages

Anxiety disorder: The initial starting dosage of lorazepam is 2 to 3 mg orally, which may be repeated 2 to 3 times daily. The recommended daily dosage should not exceed 10 mg.[11]

Insomnia due to anxiety or stress: The recommended dosage for lorazepam is 0.5 to 2 mg orally at bedtime for patients aged 65 or younger and 0.5 to 1 mg for patients aged 65 or older.

Premedication for anesthesia: When administered IM, the recommended dosage of lorazepam is 0.05 mg/kg administered 2 hours before surgery, with a maximum dose of 4 mg. If administered IV, the recommended dosage is 0.044 mg/kg administered 15 to 20 minutes before surgery, with a maximum dose of 4 mg. However, in patients aged 50 or older, the maximum dose should not exceed 2 mg.[12]

Status epilepticus: When administered IV, lorazepam is typically given at a dose of 0.1 mg/kg, up to a maximum dose of 4 mg, and at a maximum infusion rate of 2 mg/min. This dose may be repeated every 5 to 10 minutes as needed. The dose must be diluted with an equal volume of saline (1:1 dilution). According to the American Epilepsy Society guidelines, parenteral lorazepam is considered one of the first-line treatments for convulsive status epilepticus.[13]

Agitation in the intensive care unit patient: The IV loading dose for lorazepam is 0.02 to 0.04 mg/kg, with a maximum single dose of 2 mg. The maintenance dosage of lorazepam ranges from 0.02 to 0.06 mg/kg every 2 to 6 hours as needed, or a continuous infusion of 0.01 to 0.1 mg/kg/h, with a maximum dosing limit of less than 10 mg/h.

Alcohol withdrawal delirium: The IV dosage of lorazepam is 1 to 4 mg every 5 to 15 minutes until the patient is calm, with the option to repeat the dose every hour as needed. For IM administration, the lorazepam dosage is 1 to 4 mg every 30 to 60 minutes until the patient is calm, also with the option to repeat the dose every hour as needed.[14]

Alcohol withdrawal syndrome: According to the American Society of Addiction Medicine clinical practice guidelines, lorazepam is one of the most frequently used drugs for managing alcohol withdrawal. The symptom-triggered regimen can be administered orally, IM, or IV at 2 to 4 mg/h as needed, with the dose determined by a severity assessment scale. The fixed-dose regimen can be administered orally, IM, or IV at 2 mg every 6 hours for 4 doses, followed by 1 mg every 6 hours for 8 additional doses. Notably, a symptom-triggered regimen is preferred over fixed-dose regimens, requiring lower doses and shorter treatment durations. Lorazepam is preferred in patients with cirrhosis.[15][16]

Chemotherapy-associated nausea and vomiting: Lorazepam is used for breakthrough nausea or vomiting or as an adjunct to standard antiemetics. The medication can be administered orally, IV, or sublingually at a dosage of 0.5 to 2 mg every 6 hours.

Psychogenic catatonia: The IM dosage of lorazepam is 1 to 2 mg, which can be repeated after 3 hours if the initial dose is ineffective and again after another 3 hours if needed. Lorazepam can be administered orally, IM, or IV, starting with an initial dose of 1 mg, which may be repeated after 5 minutes if necessary. If the initial challenge is unsuccessful, the dosage may be increased to 4 to 8 mg daily, with treatment continuing for up to 5 days.[17]

Vertigo: According to the American Academy of Otolaryngology-Head and Neck Surgery, lorazepam is preferred at a dosage of 1 to 2 mg every 8 hours when a rapid onset of action is required to relieve vertigo in Meniere disease. However, the use of benzodiazepines is not recommended for relieving vertigo in benign paroxysmal positional vertigo.[18][19]

Severe agitation: The American College of Emergency Physicians (ACEP) advises using a combination of droperidol and midazolam or an atypical antipsychotic with midazolam for the rapid treatment of severe agitation in out-of-hospital or emergency department patients. If only one agent is used, ACEP recommends droperidol or an atypical antipsychotic. Haloperidol, alone or with lorazepam, is also recommended for effective treatment.[4]

Specific Patient Populations

Hepatic impairment: The product labeling does not provide specific information on the use of lorazepam in patients with hepatic impairment. However, as discussed, lorazepam can be used cautiously in these patients. Alcohol-associated liver disease requires comprehensive treatment addressing both liver damage and the underlying alcohol use disorder (AUD). Alcohol withdrawal syndrome complicates AUD recovery and inpatient care for liver issues. In advanced liver disease, it is recommended to select benzodiazepines with reduced hepatic metabolism, such as lorazepam.[5][9]

Renal impairment: Manufacturers recommend taking precautions when using lorazepam in patients with renal disease, such as administering frequent doses over relatively short periods. According to a review, if benzodiazepines are required, lorazepam is a reasonable first-line choice for patients with end-stage renal disease.[20]

Pregnancy considerations: Lorazepam is classified as a pregnancy category D medicine. Documented case reports and case-control studies suggest an increased risk of cleft palate and cleft lip when using lorazepam and other benzodiazepines during the first trimester. Third-trimester use of lorazepam and benzodiazepines is associated with an increased risk of causing neonatal withdrawal symptoms. If lorazepam needs to be used during pregnancy, it is recommended with extreme caution, and the benefits must outweigh the risks.[21]

Breastfeeding considerations: Lorazepam is detected in breast milk at low levels. Studies indicate that lorazepam does not cause adverse reactions in breastfed babies when mothers are taking standard dosages. Additionally, a safety scoring system evaluating psychotropic drugs used in lactating women suggests that lorazepam is safer than other benzodiazepines during breastfeeding.[22][23]

Potentially inappropriate medication in older adults: According to the American Geriatric Society Beers Criteria, lorazepam is classified as a potentially inappropriate medication for older adults. The older population typically exhibits heightened sensitivity to benzodiazepines and reduced clearance rates. Consequently, they face an elevated risk of cognitive impairment, falls, and fractures when using lorazepam. However, its use may be considered reasonable for conditions such as seizure disorders, alcohol withdrawal, severe generalized anxiety disorder, and periprocedural sedation. When prescribed, it is advised to use the lowest effective dose.[24][25]

Pediatric considerations: According to the American Epilepsy Society guidelines, IV lorazepam and IV diazepam are deemed effective in halting seizures in children (level A), whereas rectal diazepam (IM or intranasal) or buccal midazolam is considered probably effective (level B).[13]

Adverse Effects

Similar to most benzodiazepines, lorazepam can induce adverse reactions such as CNS and respiratory depression, which are dose-dependent. Additional adverse effects of the drug are observed with higher doses.[21][26]

Severe adverse effects of lorazepam include:

• Respiratory depression and failure
• Seizures
• Suicidality
• Dependency and abuse
• Tachycardia
• Hypotension
• Syncope
• Blood dyscrasias
• Jaundice
• Paradoxical reaction (hyperactive and aggressive behavior)
• Gangrene (intra-arterial)
• Withdrawal symptoms if abruptly discontinued after long-term use.
• Cognitive deficits
• Behavioral changes
• Paradoxical agitation
• Propylene glycol toxicity when using the parenteral formulation in high doses (hyponatremia and metabolic acidosis) [15][27]

Common adverse effects of lorazepam include:

• Sedation
• Dizziness
• Asthenia
• Ataxia
• Local injection site reaction
• Respiratory depression
• Hypoventilation with IV use
• Hypotension
• Fatigue
• Amnesia
• Confusion
• Disinhibition
• Irritability
• Libido changes
• Menstrual irregularities
• Diplopia
• Dysarthria
• Appetite changes
• Constipation
• Incontinence
• Urinary retention
• Dystonia
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation
• In rare instances, lorazepam can cause acute liver injury (cholestatic pattern) [28]

Drug-Drug Interactions

• Lorazepam interacts with other drugs, leading to CNS depression. Concurrent use of sedatives, hypnotics, opioids, cough and cold medicines, antiepileptics, muscle relaxers, and alcohol can worsen adverse reactions caused by lorazepam. When initiating treatment with UDP-glucuronosyltransferase (UGT) inhibitors, it is advisable to gradually taper off lorazepam to discontinue its use.

• Metronidazole should not be co-administered with propylene glycol products found in parenteral lorazepam formulations, as it may precipitate a disulfiram-like reaction.

• Kratom, a plant with partial opioid agonist effects, is widely misused in the United States. The concurrent use of kratom and benzodiazepines can significantly elevate the risk of severe CNS depression; therefore, it is crucial to avoid combining these drugs.[21][29][30][31]

Contraindications

Warnings and Precautions

Lorazepam is contraindicated in patients with a history of anaphylactic reactions to lorazepam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may occur). The use of the drug is also contraindicated in neonates or premature infants, as well as in patients with severe respiratory impairment (except during mechanical ventilation), acute narrow-angle glaucoma, sleep apnea, severe respiratory insufficiency, and when administered intra-arterially.[32] 

Lorazepam and other benzodiazepines are not recommended as first-line agents for anxiety and other psychiatric disorder symptoms during the first and third trimesters of pregnancy. Lorazepam and other benzodiazepines carry an elevated risk of abuse, misuse, and dependence. Consequently, they are contraindicated in patients who are actively using illicit substances and drugs. With the exception of patients undergoing detoxification for AUD, lorazepam and other benzodiazepines should not be used in individuals with a history of alcohol dependence or abuse who are not in remission. Combined use of alcohol and lorazepam in overdose poses an increased risk of fatality, including death.[21]

The injection formulation of lorazepam contains polyethylene glycol, propylene glycol, or benzyl alcohol, making hypersensitivity to these excipients a contraindication for use.[33] As extended-release capsules contain tartrazine, patients with a history of allergic reactions should avoid using the capsules.

Box Warning

The concurrent use of benzodiazepines with opioids can result in sedation, severe respiratory depression, coma, and death. Therefore, it is crucial to avoid the combination of these medications.[34]

Monitoring

Respiratory and cardiovascular status, blood pressure, and heart rate should be regularly monitored in patients administered lorazepam. Clinicians should monitor the patient's complete blood count, liver function tests, and lactate dehydrogenase levels for long-term therapy. In cases of high-dose or continuous IV use or patients with renal impairment, clinical signs of propylene glycol toxicity, serum creatinine, blood urea nitrogen, serum lactate, and osmolality gap should be monitored.[35] The depth of sedation should be closely monitored in critically ill patients.

Lorazepam is classified as a schedule IV drug, and patients may develop dependence and tolerance with prolonged use. Thus, utilizing the lowest effective dose of lorazepam for the shortest duration is advised. When discontinuing lorazepam, a tapering schedule of 0.5 mg every 3 days is recommended to mitigate withdrawal symptoms.[36] The dose of lorazepam should be monitored and adjusted according to the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) protocol.[37] Improvement in anxiety should be monitored using a validated scoring system such as the Hamilton Anxiety Scale.[38]

Toxicity

Signs and Symptoms of Overdose

Lorazepam can cause CNS and respiratory depression in overdose, potentially leading to hypotension, ataxia, confusion, coma, extreme drowsiness, muscle weakness, and death.[21] Concurrent use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.[39] Therefore, the prescribing of benzodiazepines and opioids together should be reserved for patients with inadequate alternative treatment options. The dosage and duration of lorazepam must be limited based on the indication, and patients require surveillance for signs and symptoms of respiratory depression. While lorazepam, similar to other benzodiazepines, is rarely associated with elevated serum ALT, clinically apparent liver injury from lorazepam is infrequent.[40] The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic. 

Management of Overdose

Flumazenil is an antidote for benzodiazepine toxicity.[41] Flumazenil competes with benzodiazepines for binding at the GABA/benzodiazepine receptor complex. However, abrupt awakening following administration can lead to dysphoria, agitation, and increased adverse effects.[42] In patients undergoing chronic benzodiazepine therapy, the sudden interruption of benzodiazepine antagonism by flumazenil may induce benzodiazepine withdrawal, including seizures. Notably, flumazenil has minimal effects on benzodiazepine-induced respiratory depression, and appropriate ventilatory support should be available when treating acute benzodiazepine overdose.[43] A recent case report detailed a severe lorazepam overdose with absent corneal, oculocephalic, and oculovestibular reflexes; however, the patient recovered after receiving 0.25 mg IV flumazenil.[44]

Enhancing Healthcare Team Outcomes

Similar to other benzodiazepine medications, lorazepam can be highly addictive. Therefore, a collaborative approach involving an interprofessional healthcare team is essential for prescribing and managing these medications. This team typically includes clinicians (MDs, DOs, NPs, and PAs), psychiatrists, nursing staff, and pharmacists, all of whom should remain vigilant for signs of misuse or adverse effects. By adopting this approach, the team can prevent misuse and unintended adverse events, ultimately optimizing therapy.

High doses or prolonged durations of lorazepam require careful consideration, especially in patients with a history of substance use disorder or concurrent opioid prescriptions. Managing such cases necessitates an interprofessional healthcare team involving nurses, pharmacists, and various specialist clinicians. This team should diligently monitor for signs of abuse, diversion, or concurrent use with other prescription or non-prescription sedative medications. Prescribers and pharmacists must closely monitor treatment, offer patient education, and exercise vigilance when prescribing benzodiazepines such as lorazepam. Additionally, the prescription drug monitoring program can help identify potential misuse of lorazepam.[45] 

During a lorazepam shortage in 2022, interdisciplinary collaboration of healthcare teams led to alternative treatment recommendations, primarily involving the use of midazolam in palliative care. Benzodiazepine utilization notably decreased during the shortage but reverted to baseline levels after its resolution. Fortunately, no patient safety events occurred, and care experiences remained unaffected. This collaborative effort effectively conserved lorazepam for patients lacking alternatives while ensuring effective management of palliative care needs.[46] Moving forward, the interprofessional healthcare team should utilize state and federal controlled substance monitoring and diversion databases to identify high-risk patients with multiple and frequent prescriptions for benzodiazepines, opioids, muscle relaxants, and other sedative-hypnotics. Safe prescribing practices are achievable only through interprofessional treatment overseen by clinicians, pharmacists, and nurses.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Hui D. Benzodiazepines for agitation in patients with delirium: selecting the right patient, right time, and right indication. Curr Opin Support Palliat Care. 2018 Dec;12(4):489-494. [PMC free article: PMC6261485] [PubMed: 30239384]

2.

Leppik IE. Status epilepticus in the elderly. Epilepsia. 2018 Oct;59 Suppl 2:140-143. [PubMed: 30159881]

3.

Berman E, Eyal S, Marom E. Trends in utilization of benzodiazepine and Z-drugs in Israel. Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1555-1560. [PubMed: 29027336]

4.

American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Severe Agitation. Thiessen MEW, Godwin SA, Hatten BW, Whittle JA, Haukoos JS, Diercks DB, Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee). Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Tomaszewski CA, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023. Ann Emerg Med. 2024 Jan;83(1):e1-e30. [PubMed: 38105109]

5.

Ratner JA, Blaney H, Rastegar DA. Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease. Hepatol Commun. 2024 Feb 01;8(2) [PMC free article: PMC10805424] [PubMed: 38251886]

6.

Elmarasi O, Abdelhady S, Mahgoub Y. Thought Blocking as a Manifestation of Catatonia: A Case Report. J Nerv Ment Dis. 2024 Feb 01;212(2):120-121. [PubMed: 38290105]

7.

Amini A, Heidari K, Asadollahi S, Habibi T, Shahrami A, Mansouri B, Kariman H. Intravenous promethazine versus lorazepam for the treatment of peripheral vertigo in the emergency department: A double blind, randomized clinical trial of efficacy and safety. J Vestib Res. 2014;24(1):39-47. [PubMed: 24594499]

8.

Vinkers CH, Tijdink JK, Luykx JJ, Vis R. [Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. Ned Tijdschr Geneeskd. 2012;155(35):A4900. [PubMed: 22929751]

9.

Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 Summer;13(2):214-23. [PMC free article: PMC3684331] [PubMed: 23789008]

10.

Yeary J, Garavaglia J, McKnight R, Smith M. Change in Management of Status Epilepticus With the Addition of Neurointensivist-Led Neurocritical Care Team at a Rural Academic Medical Center. Hosp Pharm. 2018 Oct;53(5):303-307. [PMC free article: PMC6130113] [PubMed: 30210147]

11.

Vlastra W, Delewi R, Rohling WJ, Wagenaar TC, Hirsch A, Meesterman MG, Vis MM, Wykrzykowska JJ, Koch KT, de Winter RJ, Baan J, Piek JJ, Sprangers MAG, Henriques JPS. Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. Open Heart. 2018;5(2):e000833. [PMC free article: PMC6157563] [PubMed: 30275956]

12.

Maurice-Szamburski A, Auquier P, Viarre-Oreal V, Cuvillon P, Carles M, Ripart J, Honore S, Triglia T, Loundou A, Leone M, Bruder N., PremedX Study Investigators. Effect of sedative premedication on patient experience after general anesthesia: a randomized clinical trial. JAMA. 2015 Mar 03;313(9):916-25. [PubMed: 25734733]

13.

Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. [PMC free article: PMC4749120] [PubMed: 26900382]

14.

Heavner JJ, Akgün KM, Heavner MS, Eng CC, Drew M, Jackson P, Pritchard D, Honiden S. Implementation of an ICU-Specific Alcohol Withdrawal Syndrome Management Protocol Reduces the Need for Mechanical Ventilation. Pharmacotherapy. 2018 Jul;38(7):701-713. [PubMed: 29800507]

15.

The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. [PubMed: 32511109]

16.

Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context. 2015;4:212287. [PMC free article: PMC4544271] [PubMed: 26322116]

17.

Cevher Binici N, Topal Z, Demir Samurcu N, Cansız MA, Savcı U, Öztürk Y, Özyurt G, Tufan AE. Response of Catatonia to Amisulpride and Lorazepam in an Adolescent with Schizophenia. J Child Adolesc Psychopharmacol. 2018 Mar;28(2):151-152. [PubMed: 29406775]

18.

Basura GJ, Adams ME, Monfared A, Schwartz SR, Antonelli PJ, Burkard R, Bush ML, Bykowski J, Colandrea M, Derebery J, Kelly EA, Kerber KA, Koopman CF, Kuch AA, Marcolini E, McKinnon BJ, Ruckenstein MJ, Valenzuela CV, Vosooney A, Walsh SA, Nnacheta LC, Dhepyasuwan N, Buchanan EM. Clinical Practice Guideline: Ménière's Disease. Otolaryngol Head Neck Surg. 2020 Apr;162(2_suppl):S1-S55. [PubMed: 32267799]

19.

Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA, El-Kashlan H, Fife T, Holmberg JM, Mahoney K, Hollingsworth DB, Roberts R, Seidman MD, Steiner RW, Do BT, Voelker CC, Waguespack RW, Corrigan MD. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). Otolaryngol Head Neck Surg. 2017 Mar;156(3_suppl):S1-S47. [PubMed: 28248609]

20.

Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, Beavis J, King S, Mihalyo M, Kotlinska-Lemieszek A. Prescribing Non-Opioid Drugs in End-Stage Kidney Disease. J Pain Symptom Manage. 2017 Nov;54(5):776-787. [PubMed: 28843456]

21.

Ativan (Lorazepam). J Addict Nurs. 2012 May;23(2):141-2. [PubMed: 22548613]

22.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2024. Lorazepam. [PubMed: 30000290]

23.

Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. 2021 Jan-Feb 01Am J Ther. 28(1):e118-e126. [PubMed: 30601177]

24.

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed: 30693946]

25.

Li J, Li J, Cui Y, Li H, Hou X, Zhao F, Zhao Q, Zhao J, Lin P. Effects of tranquilization therapy in elderly patients suffering from chronic non-communicable diseases: A meta-analysis. Acta Pharm. 2023 Mar 01;73(1):43-57. [PubMed: 36692463]

26.

Strand MC, Mørland J, Slørdal L, Riedel B, Innerdal C, Aamo T, Mathisrud G, Vindenes V. Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids. Forensic Sci Int. 2017 Dec;281:29-36. [PubMed: 29101905]

27.

Gonzalez J, Upadhyaya VD, Manna ZT, Sharma AR, Christopher J, Douedi S, Sen S. Paradoxical Excitation Following Intravenous Lorazepam Administration for Alcohol Withdrawal - A Case Presentation and Literature Review. J Pharm Pract. 2023 Oct;36(5):1244-1248. [PubMed: 35466771]

28.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jun 22, 2023. Lorazepam. [PubMed: 31643878]

29.

Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. J Pediatr Pharmacol Ther. 2014 Oct-Dec;19(4):277-82. [PMC free article: PMC4341412] [PubMed: 25762872]

30.

Palamar JJ. Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample. Am J Prev Med. 2021 Aug;61(2):240-245. [PMC free article: PMC8319032] [PubMed: 34027890]

31.

Singh D, Narayanan S, Grundmann O, Boyer EW, Vicknasingam B. The Use of Benzodiazepines among Kratom (Mitragyna Speciosa Korth.) Users. J Psychoactive Drugs. 2020 Jan-Mar;52(1):86-92. [PubMed: 31218929]

32.

Naso AR. Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines. Am J Health Syst Pharm. 2008 Jun 15;65(12):1180-3. [PubMed: 18541690]

33.

Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest. 2005 Sep;128(3):1674-81. [PubMed: 16162774]

34.

Aschenbrenner DS. Stronger Boxed Warning for Benzodiazepines. Am J Nurs. 2021 Mar 01;121(3):22-23. [PubMed: 33625005]

35.

Barnes BJ, Gerst C, Smith JR, Terrell AR, Mullins ME. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy. 2006 Jan;26(1):23-33. [PubMed: 16422667]

36.

Petrides AK, Melanson SEF, Kantartjis M, Le RD, Demetriou CA, Flood JG. Monitoring opioid and benzodiazepine use and abuse: Is oral fluid or urine the preferred specimen type? Clin Chim Acta. 2018 Jun;481:75-82. [PubMed: 29499200]

37.

Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar). Am J Addict. 2000 Spring;9(2):135-44. [PubMed: 10934575]

38.

Zhang M, Huang F, Jiang F, Mai M, Guo X, Zhang Y, Xu Y, Zu H. Clinical efficacy and safety of low-dose doxepin in Chinese patients with generalized anxiety disorder: A before-after study. Medicine (Baltimore). 2022 Oct 21;101(42):e31201. [PMC free article: PMC9592331] [PubMed: 36281170]

39.

Xiang J, Wu M, Lei J, Fu C, Gu J, Xu G. The fate and risk assessment of psychiatric pharmaceuticals from psychiatric hospital effluent. Ecotoxicol Environ Saf. 2018 Apr 15;150:289-296. [PubMed: 29289864]

40.

Arai T, Kogi K, Honda Y, Suzuki T, Kawai K, Okamoto M, Fujioka T, Murata N. Lorazepam as a Cause of Drug-Induced Liver Injury. Case Rep Gastroenterol. 2018 May-Aug;12(2):546-550. [PMC free article: PMC6167696] [PubMed: 30283291]

41.

Wallace IR, Campbell EC, Trimble M. Use of a flumazenil infusion to treat chlordiazepoxide toxicity. Acute Med. 2017;16(1):30-34. [PubMed: 28424803]

42.

Niedrig DF, Hoppe L, Mächler S, Russmann H, Russmann S. Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events. PLoS One. 2016;11(10):e0163224. [PMC free article: PMC5053537] [PubMed: 27711224]

43.

Rubio González V, Redondo Martín S, Ruíz López Del Prado G, Muñoz Moreno MF, Velázquez Miranda A. [Hospital Emergencies Associated with the Consumption of Hypnotics and Sedatives, 2009-2013,Castilla y León, Spain]. Rev Esp Salud Publica. 2016 Oct 24;90:e1-e12. [PubMed: 27775683]

44.

Thumtecho S, Wainipitapong S, Chunamchai S, Suteparuk S. Alprazolam and lorazepam overdose and the absence of brainstem reflexes. BMJ Case Rep. 2022 May 10;15(5) [PMC free article: PMC9092135] [PubMed: 35537772]

45.

Liang D, Guo H, Shi Y. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees. Subst Abus. 2021;42(3):294-301. [PMC free article: PMC7202951] [PubMed: 31697195]

46.

Hartung N, Fatima Z, Noreika DM, Cassel JB, Adams KS. Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection. J Pain Palliat Care Pharmacother. 2023 Dec;37(4):336-341. [PubMed: 37870502]

Disclosure: Noman Ghiasi declares no relevant financial relationships with ineligible companies.

Disclosure: Rakesh Kumar Bhansali declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.